The Retina Partners conduct research for a wide range of retinal disease and disorders, and offers patients the opportunity to participate in clinical trials and research.
ATMOSPHERE
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD
Status: Open to Enrollment
Adverum/LUNA
Multi-Center, Randomized, Open Label Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients with Neovascular (Wet) Age related Macular Degeneration (nAMD)
Status: Open to Enrollment
Ascent/RGX 3101
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
Status: Open to Enrollment
OPHEA/SHORE
A Phase III, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Status: Open to Enrollment
HONU/GE43220
HONU A Multicenter, Prospective, Observational Study of The Progression of
Intermediate Age-Related Macular Degeneration.
Status: Open to Enrollment
81201887MDG2001 (PARASOL)
A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-
Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59)
Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA)
Secondary to Age-related Macular Degeneration (AMD)
Status: Open to Enrollment
ALEXION
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of
Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-
Related Macular Degeneration (AMD)
Status: Open to Enrollment
OcuTerra/DR:EAM
A Phase 2 Randomized, Double-Masked, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
Status: Open to Enrollment
Genentech GR43828
A Phase I, Multicenter, Open-Label Study of The Safety, Tolerability, Pharmacokinetics, And Immunogenicity Of Intravitreal Injections Of Ro7446603 Alone And Co-Administered With Aflibercept In Patients With Diabetic Macular Edema
Status: Open to Enrollment
New clinical trials coming soon.
BALATON
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion
COMINO
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
EYP-1901
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD
Phase 1A (GR42163)
A Phase IA, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study Of The Safety, Tolerability, Pharmacokinetics, And Immunogenicity Of Intravitreal Injections Of Ro7303359 In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration
DX219/Oculis
A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema
Elevatum (ML43435)
Phase 3/4, open-Label, Single-Arm Study to Investigate Faricimab (Ro6867461) Treatment Response in Treatment-Naïve, Underrepresented Patients With Diabetic Macular Edema.
PAGODA
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema
PHOTON
A Randomized, Double-Masked Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients with Diabetic Macular Edema
RHONE X
A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Tolerability of Faricimab in Patients with Diabetic Macular Edema
UNITY
A Phase IIa, Prospective, Multicenter, Randomized, Double Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients With Diabetic Macular Edema
RHINE
A Phase III, Multicenter, Randomized, Double-Masked Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema
GENENTECH_GR42163
A Phase Ia, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
DERBY
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration (AMD)
GALLEGO
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
GALLEGOLE
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
CATALINA
A Phase II Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
PORTAL
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
LONGITUDE
A Longitudinal, Biomarker Study, to Explore the Composition of Aqueous Humor and the Associated Multimodal Retinal Imaging in Anti-Vegf Treatment-Naïve Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema, Before and After Aflibercept Treatment
AVONELLE-X
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration
MYLIGHT
A 52-Week Multicenter, Randomized, Double-Masked, 2-Arm Parallel Study to Compare Efficacy, Safety and Immunogenicity Of SOK583A1 To Eylea®, Administered Intravitreally, in Patients with Neovascular Age-Related Macular Degeneration
XPLORE
A Phase III, Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis in Patients with Neovascular Age-Related Macular Degeneration
PANDA
A Phase III, Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular
Age-Related Macular Degeneration (AMD) (PANDA-2) Status
ALTISSIMO
A Phase IIb Multi-Center Dose-Ranging Study Evaluating the Safety and Efficacy of a
Long-Acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-Related Macular Degeneration
CANDELA
A Randomized, Single-Masked, Active-Controlled Phase II Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
TENAYA
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration
ARCHWAY
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, And Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
GEMINI
A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy
PAVILION
A Phase III, Multicenter, Randomized Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Diabetic Retinopathy
